Physician profile
Naheed Ansari
NPI 1134208374
$696.30
in general payments reported to CMS, 2019-2025
13 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.59 · 2020: $59.24 · 2021: $121 · 2022: $145 · 2023: $58.46 · 2024: $88.94 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $173.37 | 2019-2022 | |
| Amgen INC. | $127.33 | 2021-2025 | Tavneos, Krystexxa |
| Boston Scientific Corporation | $59.50 | 2021 | |
| Scpharmaceuticals INC. | $59.09 | 2025 | |
| Csl Behring | $44.41 | 2023-2024 | Kcentra |
| Travere Therapeutics, INC. | $43.16 | 2025 | Filspari |
| Vifor Pharma, INC. | $38.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $35.93 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.13 | 2022 | |
| Aurinia Pharma U.S., INC. | $22.08 | 2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $19.95 | 2024 | |
| Akebia Therapeutics INC | $19.28 | 2021 | |
| Nxstage Medical, INC. | $19.23 | 2025 | Nxstage Cartridge Express, Nxstage System One, Pureflow Sl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naheed Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.